Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings*
- 19 June 1998
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 63 (6) , 672-681
- https://doi.org/10.1016/s0009-9236(98)90091-1
Abstract
The aim of this study was to test the hypothesis that nimesulide, a nonsteroidal antiinflammatory drug, or its principal metabolite 4-hydroxynimesulide, is a selective inhibitor of prostaglandin H synthase-2 in human beings. Heparinized whole blood samples obtained from healthy subjects were incubated with lipopolysaccharide (10 micrograms/ml) for 24 hours at 37 degrees C and prostaglandin E2 was measured in plasma as an index of monocyte prostaglandin H synthase-2 activity. The production of thromboxane B2 in whole blood allowed to clot at 37 degrees C for 60 minutes was assessed as an index of platelet prostaglandin H synthase-1 activity. We also measured the urinary excretion of 11-dehydrothromboxane B2, prostaglandin E2, 6-ketoprostaglandin F1 alpha, and thromboxane B2 as in vivo indexes of cyclooxygenase activity. All prostanoids were measured by previously validated radioimmunoassay techniques. In the whole blood assays in vitro, nimesulide was twentyfold more potent than 4-hydroxynimesulide toward the two isozymes and both compounds displayed a twentyfold preference for prostaglandin H synthase-2 versus prostaglandin H synthase-1. The administration of a single oral dose of 100 mg nimesulide to six healthy subjects significantly (p < 0.01) reduced monocyte prostaglandin H synthase-2 and prostaglandin H synthase-1 activity ex vivo by more than 90% and 50%, respectively, up to 6 hours. At 24 hours, prostaglandin H synthase-2 but not prostaglandin H synthase-1 activity was significantly reduced by 49% (p < 0.05). Nimesulide significantly (p < 0.05) reduced the urinary excretion of 11-dehydrothromboxane B2 and 6-ketoprostaglandin F1 alpha by approximately 30% and 25%, respectively, while not affecting that of prostaglandin E2 and thromboxane B2. Nimesulide is a potent inhibitor of human monocyte prostaglandin H synthase-2. However, despite a twentyfold selectivity ratio, therapeutic plasma levels of nimesulide are sufficiently high to cause detectable inhibition of platelet prostaglandin H synthase-1.Keywords
This publication has 29 references indexed in Scilit:
- Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agentsNature, 1996
- NimesulideDrugs, 1994
- The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1Nature, 1994
- Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissuesFEBS Letters, 1993
- The Pharmacokinetic Profile of Nimesulide in Healthy VolunteersDrugs, 1993
- A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+-dependent translocation domain with homology to PKC and GAPCell, 1991
- Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urineBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1987
- Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the ratInflammation Research, 1986
- Evidence for a Direct Stimulatory Effect of Prostacyclin on Renin Release in ManJournal of Clinical Investigation, 1982
- The Glomerular Permeability Determined by Dextran Clearance Using Sephadex Gel FiltrationScandinavian Journal of Clinical and Laboratory Investigation, 1968